Adult Dosing
Non-small cell lung cancer
Monotherapy
Combination therapy
- 25 mg/m2 IV qwk in combination with cisplatin
- Alt: 30 mg/m2 IV given in combination with cisplatin on days 1 and 29, then q6 wks with cisplatin
Dose modifications for hematologic toxicity
- Based on granulocyte cells/mm3
- Granulocyte count > = 1500: 100% of dose
- Granulocyte count 1000-1499: 50% of dose
- Granulocyte count < 1000: Do not administer. Repeat granulocyte count in 1 wk. If 3 consecutive weeks, granulocyte count < 1000, discontinue therapy
- If fever, sepsis while granulocytopenia and 2 consecutive weekly doses held due to granulocytopenia, follow dose adjustments as
- Granulocyte count > 1500: 75% of dose
- Granulocyte count 1000-1499: 37.5% of dose
- Granulocyte count < 1000: Do not administer. Repeat granulocyte count in 1 wk. If 3 consecutive weeks, granulocyte count < 1000, discontinue therapy
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Administer in carefully adjusted doses under supervision of a physician experienced in cancer chemotherapy. Monitor patients frequently for myelosuppression. Monitor CBC w/ differential count on day of therapy prior to each dose and if cisplatin combination therapy continue qwk
- Intrathecal use of other vinca alkaloids has been fatal. It is for IV use only, fatal if given intrathecally
- Acute shortness of breath and severe bronchospasm have been reported infrequently following the administration. This may require treatment with supplemental oxygen, bronchodilators, and/or corticosteroids, particularly when there is pre-existing pulmonary dysfunction
Cautions: Use cautiously in
- Hepatic impairment
- Debilitated patients
- Myelosuppression
- Neuropathy
- Pulmonary impairment
- Hx. of XRT
Pregnancy Category:D
Breastfeeding: It is not known whether vinorelbine is excreted in human breastmilk. Since many drugs are excreted in human milk and due to the potential for serious adverse reactions, use is not recommended
